CFON-026, a best-in-class macrocyclic non-covalent BTK inhibitor targeting WT and all clinically relevant mutant variants

Yvonne G.T.H. van Mil, Joost C.M. Uitdehaag, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Michelle Muller, Winfried R. Mulder, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik Ensing, Rogier C. Buijsman.